Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + cetuximab + β-blocker in late-stage colorectal cancer (second-line)
ChiCTR2600116223Phase 4Recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Jan 2026
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of durvalumab, cetuximab and carvedilol in colorectal cancer (CRC), sponsored by Shanghai East Hospital. Primary endpoint: Objective response rate. Started Jan 2026; status: recruiting.
02
Drugs
durvalumabcetuximabcarvedilol
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2600116223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116223.